GSK's $10.6 Billion Bet on Cancer Drug Developer Nuvalent

GSK's largest acquisition in recent years, a $10.6 billion purchase of cancer drug developer Nuvalent, signifies a new strategic direction under CEO Luke Miels, focusing on oncology to drive growth and compete with industry rivals. The deal values Nuvalent shares at a 40% premium.

GSK has announced a landmark acquisition, unveiling plans to purchase U.S.-based cancer drug developer Nuvalent for $10.6 billion. This all-cash transaction represents a substantial strategic shift under CEO Luke Miels, marking GSK's intensified focus on oncology as it aims to strengthen its drug discovery pipeline.

The agreement, valuing Nuvalent shares at approximately $124 each—a 40% premium over its previous closing price—highlights a departure from GSK’s conventional strategy of smaller, incremental acquisitions. Under Miels, who succeeded Emma Walmsley earlier this year, the company endeavors to achieve more than £40 billion in revenue by 2031 while addressing the 2028 patent expiration of its HIV treatment, dolutegravir.

Expected to enhance GSK's sales forecasts, the purchase is seen as significantly boosting treatment options for lung cancer patients. GSK aims to close the gap with competitor AstraZeneca in the cancer drugs market, where AstraZeneca leads with 44% of its sales rooted in oncology. Financially, the investment is estimated at $9.4 billion net of cash acquired, with completion slated for the third quarter of 2026.